RWD Key To Scottish Orkambi Deal
Vertex has managed to secure a deal to provide Scottish cystic fibrosis patients with access to Orkambi and Symkevi. The promise of real world data and a price discount has convinced the Scottish government to say yes to the treatments, which had earlier been rejected by the Scottish Medicines Consortium.
You may also be interested in...
US Pharma Firms Not In Post-Brexit Trade Talks
A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions
Vertex Finally Inks Orkambi Deal In England
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
At Last: Vertex Strikes CF Deal In England
After years of stalemate, NHS England and Vertex have finally agreed a deal that will see cystic fibrosis patients access Orkambi and Symkevi as well as allow more patients to benefit from Kalydeco.